We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Arecor Therapeutics Plc | LSE:AREC | London | Ordinary Share | GB00BMWLM973 | ORD GBP0.01 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 136.50 | 133.00 | 140.00 | 136.50 | 136.50 | 136.50 | 10,969 | 08:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Coml Physical, Biologcl Resh | 3.54M | -9.26M | -0.3024 | -4.51 | 41.8M |
TIDMAREC
RNS Number : 0629K
Arecor Therapeutics PLC
27 August 2021
Arecor Therapeutics plc
("Arecor", the "Company" or the "Group")
APPOINTMENT OF GRANT THORNTON AS AUDITOR
Cambridge, UK, 27 August 2021: Arecor Therapeutics plc (AIM: AREC), a globally focused biopharmaceutical group advancing today's therapies to enable healthier lives, today announces that Grant Thornton UK LLP ("Grant Thornton") have been appointed as the Group's auditor, with immediate effect. Lakin Rose Limited has resigned as the auditor of Arecor Limited.
The Board's decision to appoint auditors for the Group was made following a consultation process. Grant Thornton was chosen based on their public company expertise, reputation and experience. Lakin Rose has confirmed that it is not aware of any circumstances connected with its cessation as auditor of Arecor Limited that it considers should be brought to the attention of the Board, creditors or shareholders.
In accordance with section 327(c) of the Corporations Act 2001, a resolution will be tabled at the Company's 2021 Annual General Meeting to ratify the appointment of Grant Thornton as the Group's auditor.
The Board of Directors would like to take this opportunity to thank Lakin Rose UK LLP for their assistance and services to Arecor Limited.
This announcement contains inside information for the purposes of the retained UK version of the EU Market Abuse Regulation (EU) 596/2014 ("UK MAR").
-ENDS-
For more information, please contact:
Arecor Therapeutics plc www.arecor.com Dr Sarah Howell, Chief Executive Officer Tel: +44 (0) 1223 426060 Email: info@arecor.com Susan Lowther, Chief Financial Officer Tel: +44 (0) 1223 426060 Email: info@arecor.com Mo Noonan, Communications Tel: +44 (0) 7876 444977 Email: mo.noonan@arecor.com Panmure Gordon (UK) Limited (NOMAD and Broker) Freddy Crossley, Emma Earl (Corporate Tel: +44 (0) 20 7886 2500 Finance) Rupert Dearden (Corporate Broking) Consilium Strategic Communications Chris Gardner, David Daley, Angela Tel: +44 (0) 20 3709 5700 Gray Email: arecor@consilium-comms.com
Notes to Editors
About Arecor
Arecor Therapeutics plc is a globally focused biopharmaceutical group transforming patient care by bringing innovative medicines to market through the enhancement of existing therapeutic products. By applying our innovative proprietary formulation technology platform, Arestat(TM), we are developing an internal portfolio of proprietary products in diabetes and other indications, as well as working with leading pharmaceutical and biotechnology companies to deliver enhanced formulations of their therapeutic products. The Arestat(TM) platform is supported by an extensive patent portfolio.
For further details please see our website, www.arecor.com
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
MSCPRMTTMTJTBLB
(END) Dow Jones Newswires
August 27, 2021 08:40 ET (12:40 GMT)
1 Year Arecor Therapeutics Chart |
1 Month Arecor Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions